PPARA and metabolic disease: Ongoing work in sirtuin-targeted drug discovery (28) may ultimately lead to the consideration of SIRT1 inhibitors as therapeutic alternatives to or amplifiers of PPARα agonists (e.g., fibrates) for metabolic disorders.